User Image Cart Icon 0 Search Image
  • Home > Blog > K Opiod Receptor & Addiction

K Opiod Receptor & Addiction

  1. μ-Opposing actions of the κ–opiod Receptor
  2. Structure of the human κ–opiod Receptor in complex with JDTic
  3. The dynorphin/κ–opiod Receptor system and its role in psychiatric disorders
  4. Development of κ opiod Receptor antagonists
  5. Dynorphin is a specific endogenous ligand of the κ opiod Receptor
  6. Molecular cloning and tissue distribution of a putative member of the rat opiod Receptor gene family that is not a μ, δ or κ opiod Receptor type
  7. Molecular cloning of a rat κ opiod Receptor reveals sequence similarities to the μ and δ opiod Receptors
  8. Quantitative autoradiographic mapping of μ-, δ-and κ–opiod Receptors in knockout mice lacking the μ-opiod Receptor gene
  9. κ–opiod Receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction
  10. Molecular cloning and expression of a rat κ opiod Receptor
  11. Cloning of a human κ opiod Receptor from the brain
  12. Pharmacological properties of JDTic: A novel κ–opiod Receptor antagonist
  13. κ opiod Receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses
  14. μ-and κ–opiod Receptor-meiated opiod effects on social play in juvenile rats
  15. Antipruritic activity of the κ–opiod Receptor agonist, TRK-820
  16. Effects of κ–opiod Receptor ligands on intracranial self-stimulation in rats
  17. CI‐977, a novel and selective agonist for the κ‐opiod Receptor
  18. Depressive-like effects of the κ–opiod Receptor agonist salvinorin A on behavior and neurochemistry in rats
  19. Cellular mechanism for anti-analgesic action of agonists of the κ–opiod Receptor
  20. GEC1 interacts with the κ opiod Receptor and enhances expression of the Receptor
  21. Modulation of the behavioral and neurochemical effects of psychostimulants by κ‐opiod Receptor systems
  22. The role of κ–opiod Receptor activation in mediating antinociception and addiction
  23. 5′-Guanidinonaltrindole, a highly selective and potent κ–opiod Receptor antagonist
  24. The role of the dynorphin/κ opiod Receptor system in anxiety
  25. Structure and chromosomal mapping of genes for the mouse κ–opiod Receptor and an opiod Receptor homologue (MOR-C)
  26. Asymmetric synthesis of salvinorin A, a potent κ opiod Receptor agonist
  27. Formation of μ-/κ–opiod Receptor heterodimer is sex-dependent and mediates female-specific opiod analgesia
  28. The intrinsic antinociceptive effects of oxycodone appear to be κ–opiod Receptor mediated
  29. Neuropathic pain activates the endogenous κ opiod system in mouse spinal cord and induces opiod Receptor tolerance
  30. Isolation of a human κ opiod Receptor cDNA from placenta
  31. Antidepressant-like effects of κ–opiod Receptor antagonists in the forced swim test in rats
  32. Research and development of κ opiod Receptor agonists and δ opiod Receptor agonists
  33. Anxiolytic-like effects of κ–opiod Receptor antagonists in models of unlearned and learned fear in rats
  34. Discovery of aminobenzyloxyarylamides as κ opiod Receptor selective antagonists: application to preclinical development of a κ opiod Receptor antagonist Receptor …
  35. Distinct mechanisms for activation of the opiod Receptor-like 1 and κ–opiod Receptors by nociceptin and dynorphin A
  36. Localization of the κ opiod Receptor in lipid rafts
  37. Salvinorin A: a novel and highly selective κ–opiod Receptor agonist
  38. Big dynorphin as a putative endogenous ligand for the κ‐opiod Receptor
  39. Primary astroglial cultures derived from several rat brain regions differentially express μ, δ and κ opiod Receptor mRNA
  40. Quantitative autoradiography of μ-, δ-and κ1 opiod Receptors in κ–opiod Receptor knockout mice
  41. Studies toward the pharmacophore of salvinorin A, a potent κ opiod Receptor agonist
  42. U50, 488, a κ opiod Receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats
  43. Long term κ–opiod Receptor blockade following nor-binaltorphimine
  44. Identification of novel functionally selective κ–opiod Receptor scaffolds
  45. 2-Methoxymethyl-salvinorin B is a potent κ opiod Receptor agonist with longer lasting action in vivo than salvinorin A
  46. Systemic κ‐opiod Receptor antagonism by nor‐binaltorphimine reduces dependence‐induced excessive alcohol self‐administration in rats
  47. Synthesis and κ–opiod Receptor activity of furan-substituted salvinorin A analogues
  48. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious κ–opiod Receptor agonist: structural and functional …
  49. Endogenous κ–opiod Receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine
  50. The selective κ–opiod Receptor agonist U50, 488H attenuates voluntary ethanol intake in the rat
  51. Novel opiod cyclic tetrapeptides: Trp isomers of CJ‐15,208 exhibit distinct opiod Receptor agonism and short‐acting κ opiod Receptor antagonism
  52. μ-, δ-and κ–opiod Receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer’s disease patients
  53. Distribution of κ opiod Receptor mRNA in adult mouse brain: an in situ hybridization histochemistry study
  54. Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of κ–opiod Receptor-1 knockout mice
  55. Potent antinociceptive effects of TRK-820, a novel κ–opiod Receptor agonist
  56. Decreased oral self‐administration of alcohol in κ‐opiod Receptor knock‐out mice
  57. κ–opiod Receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine
  58. The effects of spiradoline (U‐62066E), a κ‐opiod Receptor agonist, on neuroendocrine function in man
  59. Chemotype-selective modes of action of κ–opiod Receptor agonists
  60. The G protein–biased κ–opiod Receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo
  61. The expression of δ-and κ–opiod Receptor is enhanced during intestinal inflammation in mice
  62. Characterization of mechanical withdrawal responses and effects of μ-, δ-and κ–opiod agonists in normal and μ-opiod Receptor knockout mice
  63. Molecular interaction between butorphanol and κ–opiod Receptor
  64. κ–opiod Receptor is colocalized in GnRH and KNDy cells in the female ovine and rat brain
  65. Antidepressant-like effects of κ–opiod Receptor antagonists in Wistar Kyoto rats
  66. Exploration of the SAR connection between morphinan-and arylacetamide-based κ opiod Receptor (κOR) agonists using the strategy of bridging
  67. Hallucinatory and rewarding effect of salvinorin A in zebrafish: κ–opiod and CB1-cannabinoid Receptor involvement
  68. Neuroprotective actions of GR89696, a highly potent and selective κ‐opiod Receptor agonist
  69. Buprenorphine is a potent κ–opiod Receptor antagonist in pigeons and mice
  70. Functional interaction among opiod Receptor types: up-regulation of μ-and δ-opiod Receptor functions after repeated stimulation of κ–opiod Receptors
  71. Analgesia from a peripherally active κ–opiod Receptor agonist in patients with chronic pancreatitis
  72. Strategies for developing κ opiod Receptor agonists for the treatment of pain with fewer side effects
  73. Agonist‐induced phosphorylation of the κ‐opiod Receptor
  74. Sensitization to the behavioral effects of cocaine: modulation by dynorphin and κ–opiod Receptor agonists
  75. Isolation of a novel cDNA encoding a putative membrane Receptor with high homology to the cloned μ, δ, and κ opiod Receptors
  76. Sex-related differences in mechanical nociception and antinociception produced by μ-and κ–opiod Receptor agonists in rats
  77. Bi-directional heterologous desensitization between the major HIV-1 co-Receptor CXCR4 and the κ–opiod Receptor
  78. Disruption of the κ–opiod Receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ-agonist U-50,488 H …
  79. Toward a structure-based model of salvinorin A recognition of the κ–opiod Receptor
  80. Regional, developmental, and cell cycle‐dependent differences in μ, δ, and κ‐opiod Receptor expression among cultured mouse astrocytes
  81. Synthesis and evaluation of 11C-LY2795050 as a κ–opiod Receptor antagonist radiotracer for PET imaging
  82. Gz coupling to the rat κ–opiod Receptor
  83. Noribogaine is a G-protein biased κ–opiod Receptor agonist
  84. Involvement of the κ–opiod Receptor in the anxiogenic-like effect of CP 55,940 in male rats
  85. Detection of opiod Receptor mRNA by RT-PCR reveals alternative splicing for the δ-and κ–opiod Receptors
  86. Autoradiography of [3H] U-69593 binding sites in rat brain: evidence for κ opiod Receptor subtypes
  87. LPK-26, a novel κ–opiod Receptor agonist with potent antinociceptive effects and low dependence potential
  88. Hippocampal dynorphin B injections impair spatial learning in rats: a κ–opiod Receptor-mediated effect
  89. PD117302: a selective agonist for the κ‐opiod Receptor
  90. Long-acting κ opiod antagonists disrupt Receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase
  91. Double in situ hybridization study on coexistence of μ-, δ-and κ–opiod Receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root ganglia
  92. Norbinaltorphimine, a selective κ–opiod Receptor antagonist, induces an itch-associated response in mice
  93. Enhanced κ–opiod Receptor-mediated analgesia by antisense targeting the σ1 Receptor
  94. Differential agonist regulation of the human κ‐opiod Receptor
  95. δ-, but not μ-and κ-, opiod Receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury
  96. κ–opiod Receptor activation modulates Ca2+ currents and secretion in isolated neuroendocrine nerve terminals
  97. The μ‐opiod Receptor agonist morphine, but not agonists at δ‐or κ‐opiod Receptors, induces peripheral antinociception mediated by cannabinoid Receptors
  98. … -based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the κ–opiod Receptor
  99. Mechanisms of agonist-induced down-regulation of the human κ–opiod Receptor: internalization is required for down-regulation
  100. Dynorphin peptides differentially regulate the human κ opiod Receptor
  101. Functional effects of systemically administered agonists and antagonists of μ, δ, and κ opiod Receptor subtypes on body temperature in mice
  102. Murine chromosomal location of the μ and κ opiod Receptor genes
  103. Duration of action of a broad range of selective κ–opiod Receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation
  104. Receptor‐selective changes in µ‐, δ‐and κ‐opiod Receptors after chronic naltrexone treatment in mice
  105. Synthesis of CJ-15,208, a novel κ–opiod Receptor antagonist
  106. Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted κ–opiod Receptor agonists
  107. Chronic muscle pain induced by repeated acid injection is reversed by spinally administered μ-and δ-, but not κ-, opiod Receptor agonists
  108. κ opiod Receptor ligands regulate angiogenesis in development and in tumours
  109. Phosphorylation of a carboxyl-terminal serine within the κ–opiod Receptor produces desensitization and internalization
  110. Association of in vivo κ–opiod Receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology
  111. Autoradiographic mapping of the opiod Receptor-like 1 (ORL1) Receptor in the brains of μ-, δ-or κ–opiod Receptor knockout mice
  112. Transformation of a κ–opiod Receptor Antagonist to a κ-Agonist by Transfer of a Guanidinium Group from the 5 ‘-to 6 ‘-Position of Naltrindole
  113. Modulation of anxiety-related behaviors by μ-and κ–opiod Receptor agonists depends on the social status of mice
  114. U50, 488H-induced internalization of the human κ opiod Receptor involves a β-arrestin-and dynamin-dependent mechanism: κ Receptor internalization is not …
  115. Repeated exposure to the κ–opiod Receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity
  116. Mechanism of diuretic action of U-62,066 E, a κ opiod Receptor agonist
  117. Anxiety and ethanol consumption in victorious and defeated mice; effect of κ–opiod Receptor activation
  118. The atomistic level structure for the activated human κ–opiod Receptor bound to the full Gi protein and the MP1104 agonist
  119. DAMGO, a μ‐opiod Receptor selective ligand, distinguishes between μ‐and κ‐opiod Receptors at a different region from that for the distinction between μ‐and δ …
  120. Properties of a κ–opiod Receptor expressed in CHO cells: interaction with multiple G-proteins is not specific for any individual Gα subunit and is similar to that of other …
  121. Abuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed μ-and κ–opiod Receptor agonist and δ-opiod Receptor antagonist
  122. Suppression of the GnRH pulse generator by neurokinin B involves a κ–opiod Receptor-dependent mechanism
  123. Agonist-promoted Lys63-linked polyubiquitination of the human κ–opiod Receptor is involved in Receptor down-regulation
  124. Suppression of morphine withdrawal by electroacupuncture in rats: dynorphin and κ–opiod Receptor implicated
  125. Stress-induced activation of the dynorphin/κ–opiod Receptor system in the amygdala potentiates nicotine conditioned place preference
  126. 6′-Guanidinonaltrindole (6′-GNTI) is a G protein-biased κ–opiod Receptor agonist that inhibits arrestin recruitment
  127. Pharmacology and anti‐addiction effects of the novel κ opiod Receptor agonist M esyl S al B, a potent and long‐acting analogue of salvinorin A
  128. Essential structure of the κ opiod Receptor agonist nalfurafine for binding to the κ Receptor
  129. Pharmacological properties of TRK-820 on cloned μ-, δ-and κ–opiod Receptors and nociceptin Receptor
  130. Agonist-dependent desensitization of the κ opiod Receptor by G protein Receptor kinase and β-arrestin
  131. The κ opiod Receptor and food intake
  132. Identification of short-acting κ–opiod Receptor antagonists with anxiolytic-like activity
  133. Hypothalamic κ–opiod Receptor modulates the orexigenic effect of ghrelin
  134. Cardioprotection of preconditioning by metabolic inhibition in the rat ventricular myocyte: involvement of κ–opiod Receptor
  135. Central nicotine induces browning through hypothalamic κ opiod Receptor
  136. Central κ–opiod Receptor-mediated antidepressant-like effects of nor-Binaltorphimine: Behavioral and BDNF mRNA expression studies
  137. Antagonists of the κ‐opiod Receptor enhance allodynia in rats and mice after sciatic nerve ligation
  138. A regulatory variation in OPRK1, the gene encoding the κ–opiod Receptor, is associated with alcohol dependence
  139. κ–opiod Receptor-transfected cell lines: modulation of adenylyl cyclase activity following acute and chronic opiod treatments
  140. κ–opiod Receptor agonist U50, 488H modulates cocaine and morphine self-administration in drug-naive rats and mice
  141. Hypoxia induces internalization of κ–opiod Receptor
  142. Immunomodulatory action of class μ, δ-and κ–opiod Receptor agonists in mice
  143. L-type Ca2+ channel modulation by dihydropyridines potentiates κ–opiod Receptor agonist induced acute analgesia and inhibits development of tolerance in rats
  144. Immunosuppression by δ-opiod antagonist naltrindole: δ-and triple μ/δ/κ–opiod Receptor knockout mice reveal a nonopiod activity
  145. Exposure to the selective κ–opiod Receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats
  146. Analgesic efficacy of peripheral κ–opiod Receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective …
  147. Copb1-facilitated axonal transport and translation of κ opiod–Receptor mRNA
  148. Pulsed magnetic field induced “analgesia” in the land snail, Cepaea nemoralis, and the effects of μ, δ, and κ opiod Receptor agonists/antagonists
  149. Increased κ–opiod Receptor expression and function during chronic visceral hypersensitivity
  150. Role of κ–opiod Receptor activation in pharmacological preconditioning of swine
  151. Antidepressive effects of the κ–opiod Receptor agonist salvinorin A in a rat model of anhedonia
  152. Region selective up-regulation of μ-, δ-and κ–opiod Receptors but not opiod Receptor-like 1 Receptors in the brains of enkephalin and dynorphin knockout mice
  153. Stimulation of κ–opiod Receptor reduces isoprenaline-induced cardiac hypertrophy and fibrosis
  154. Targeting opiod Receptor signaling in depression: do we need selective κ opiod Receptor antagonists?
  155. κ–opiod Receptor activation in dopamine neurons disrupts behavioral inhibition
  156. In situ hybridization study of μ-and κ–opiod Receptor mRNAs in the rat spinal cord and dorsal root ganglia
  157. Chemical coding of neurons expressing δ-and κ–opiod Receptor and type I vanilloid Receptor immunoreactivities in the porcine ileum
  158. Behavioral stress may increase the rewarding valence of cocaine-associated cues through a dynorphin/κ–opiod Receptor-mediated mechanism without …
  159. Allosterism within δ opiod–κ opiod Receptor Heteromers in Peripheral Sensory Neurons: Regulation of κ opiod Agonist Efficacy
  160. κ–opiod Receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes
  161. Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opiod Receptor agonist
  162. Receptor occupancy of the κ–opiod antagonist LY2456302 measured with positron emission tomography and the novel radiotracer 11C-LY2795050
  163. Axonal mRNA transport and localized translational regulation of κ–opiod Receptor in primary neurons of dorsal root ganglia
  164. Pharmacological activities of optically pure enantiomers of the κ opiod agonist, U50, 488, and its cis diastereomer: evidence for three κ Receptor subtypes
  165. κ–opiod Receptor stimulation modulates TLR4/NF-κB signaling in the rat heart subjected to ischemia–reperfusion
  166. Regulation of mouse κ opiod Receptor gene expression by retinoids
  167. Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a κ–opiod Receptor
  168. The macrocyclic tetrapeptide [D‐T rp] CJ‐15,208 produces short‐acting κ opiod Receptor antagonism in the CNS after oral administration
  169. Effects of peripherally restricted κ opiod Receptor agonists on pain-related stimulation and depression of behavior in rats
  170. κ opiod Receptor-mediated analgesia in the developing rat
  171. Antiarrhythmic effect mediated by κ–opiod Receptor is associated with Cx43 stabilization
  172. Phosphatidylinositol‐3 kinase is distinctively required for µ‐, but not κ‐opiod Receptor‐induced activation of c‐Jun N‐terminal kinase
  173. κ–opiod Receptor participates of NSAIDs peripheral antinociception
  174. Selective changes in μ, δ and ϰ opiod Receptor binding in certain limbic regions of the brain in Alzheimer’s disease patients
  175. Sequence of κ–opiod Receptor cDNA in the R1. 1 thymoma cell line
  176. Development of novel quinoxaline-based κ–opiod Receptor agonists for the treatment of neuroinflammation
  177. Prodynorphin, proenkephalin and κ opiod Receptor mRNA responses to acute “binge” cocaine
  178. Effects of atypical κ–opiod Receptor agonists on intrathecal morphine-induced itch and analgesia in primates
  179. Repeated stress dysregulates κ–opiod Receptor signaling in the dorsal raphe through a p38α MAPK-dependent mechanism
  180. Molecular switches of the κ opiod Receptor triggered by 6′-GNTI and 5′-GNTI
  181. Sodium channel blocking actions of the κ–opiod Receptor agonist U50, 488 contribute to its visceral antinociceptive effects
  182. Sensitization to the conditioned rewarding effects of morphine and cocaine: differential effects of the κ–opiod Receptor agonist U69593
  183. An electrophysiological basis for the antiarrhythmic actions of the κ–opiod Receptor agonist U-50,488 H
  184. In situ hybridization study of κ–opiod Receptor mRNA in the rat brain
  185. Effects of a newly synthesized κ–opiod Receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats
  186. Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ–opiod Receptor antagonist JDTic
  187. Effects of the κ–opiod Receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat
  188. opiod Receptor-mediated suppression of humoral immune response in vivo and in vitro: involvement of κ opiod Receptors
  189. Lack of cross-tolerance between U69, 593 and bremazocine suggest κ–opiod Receptor multiplicity in mice
  190. Impact of pharmacological manipulation of the κ–opiod Receptor system on self-grooming and anhedonic-like behaviors in male mice
  191. Test–retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the κ opiod Receptor
  192. Effects of peripheral κ opiod Receptor activation on inflammatory mechanical hyperalgesia in male and female rats
  193. μ-, δ-, and κ–opiod Receptor agonists selectively modulate sexual behaviors in the female rat: differential dependence on progesterone
  194. Structure and expression of a rat κ opiod Receptor gene
  195. Myocardial apoptosis and infarction after ischemia/reperfusion are attenuated by κ–opiod Receptor agonist
  196. Investigation of inactive-state κ opiod Receptor homodimerization via single-molecule microscopy using new antagonistic fluorescent probes
  197. N-Glycosylation of the Human κ opiod Receptor Enhances Its Stability but Slows Its Trafficking along the Biosynthesis Pathway
  198. Further evidence for the implication of a κ–opiod Receptor mechanism in the production of psychological stress-induced analgesia
  199. Toosendanin-induced apoptosis in colorectal cancer cells is associated with the κ–opiod Receptor/β-catenin signaling axis
  200. κ–opiod Receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative …
  201. Feeding responses to μ-, δ-and κ–opiod Receptor agonists in the meat-type chick
  202. κ–opiod Receptor activation promotes mitochondrial fusion and enhances myocardial resistance to ischemia and reperfusion injury via STAT3-OPA1 pathway
  203. Constraining endomorphin-1 by β, α-hybrid dipeptide/heterocycle scaffolds: identification of a novel κ–opiod Receptor selective partial agonist
  204. G protein signaling–biased agonism at the κ–opiod Receptor is maintained in striatal neurons
  205. Dynorphin and κ–opiod Receptor dysregulation in the dopaminergic reward system of human alcoholics
  206. Identification of the three-dimensional pharmacophore of κ–opiod Receptor agonists
  207. Antinociceptive and Adverse Effects of µ‐and κ‐opiod Receptor Agonists: A Comparison of Morphine and U50488‐H
  208. Conformational analysis and automated Receptor docking of selective arylacetamide-based κ–opiod agonists
  209. Beneficial effects of the κ opiod Receptor agonist U-50488H in experimental acute brain and spinal cord injury
  210. Effect of κ–opiod Receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells
  211. An improved antagonist radiotracer for the κ–opiod Receptor: Synthesis and characterization of 11C-LY2459989
  212. κ–opiod Receptor agonists modulate visceral nociception at a novel, peripheral site of action
  213. Visualizing preference of G protein-coupled Receptor kinase 3 for the process of κ–opiod Receptor sequestration
  214. μ-, δ-and κ–opiod Receptor-mediated inhibition of neurotransmitter release and adenylate cyclase activity in rat brain slices: studies with fentanyl isothiocyanate
  215. Sex difference in κ–opiod Receptor (KOPR)-mediated behaviors, brain region KOPR level and KOPR-mediated guanosine 5′-O-(3-[35S] thiotriphosphate) binding in …
  216. Early role of the κ opiod Receptor in ethanol-induced reinforcement
  217. Structure–Activity Relationships of [des-Arg7]Dynorphin A Analogues at the κ opiod Receptor
  218. Prodynorphin and κ opiod Receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders
  219. Post-transcriptional regulation of mouse κ–opiod Receptor expression
  220. Trial-selective effects of U50, 488H, a κ–opiod Receptor agonist, on consummatory successive negative contrast
  221. Development and in vivo evaluation of a κ–opiod Receptor agonist as a PET radiotracer with superior imaging characteristics
  222. Anti-arrhythmic effect of κ–opiod Receptor stimulation in the perfused rat heart: involvement of a cAMP-dependent pathway
  223. Anti‐nociception mediated by a κ opiod Receptor agonist is blocked by a δ Receptor agonist
  224. Voluntary ethanol intake predicts κ–opiod Receptor supersensitivity and regionally distinct dopaminergic adaptations in macaques
  225. Spinal κ–opiod Receptor-mediated antinociception is stimulus-specific
  226. Characterization of a Knock-In Mouse Line Expressing a Fusion Protein of κ opiod Receptor Conjugated with tdTomato: 3-Dimensional Brain Imaging via …
  227. Neuroanatomical and neuropharmacological study of opiod pathways in the mesencephalic tectum: effect of μ1-and κ–opiod Receptor blockade on escape behavior …
  228. Regulation of κ–opiod Receptor signaling in peripheral sensory neurons in vitro and in vivo
  229. Activity profiles of dalargin and its analogues in μ‐, δ‐ and κ‐opiod Receptor selective bioassays
  230. Elucidation of conformational states, dynamics, and mechanism of binding in human κ–opiod Receptor complexes
  231. Modeling of κ–opiod Receptor/agonists interactions using pharmacophore-based and docking simulations
  232. Prenatal ethanol increases ethanol intake throughout adolescence, alters ethanol‐mediated aversive learning, and affects μ but not δ or κ opiod Receptor mRNA …
  233. Presence of μ and κ opiod Receptor mRNAs in galanin but not in GnRH neurons in the female rat
  234. Prolonged opportunity for ischemic neuroprotection with selective κ–opiod Receptor agonist in rats
  235. Hyaluronic acid induces activation of the κ–opiod Receptor
  236. The novel κ–opiod Receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice
  237. Characterization of κ–opiod Receptor transcripts expressed by T cells and macrophages
  238. 8-epi-Salvinorin B: crystal structure and affinity at the κ opiod Receptor
  239. Suppression of cAMP by phosphoinositol/Ca2+ pathway in the cardiac κ–opiod Receptor
  240. Endogenous κ opiod Receptor Systems Modulate the Responsiveness of Mesoaccumbal Dopamine Neurons to Ethanol
  241. Effects of κ–opiod Receptor agonists on long-term cocaine use and dopamine neurotransmission
  242. Blockade of U50, 488H analgesia by antisense oligodeoxynucleotides to a κ–opiod Receptor
  243. Intrinsic relative activities of κ opiod agonists in activating Gα proteins and internalizing Receptor: Differences between human and mouse Receptors
  244. … of CYX-6, a potent μ-opiod Receptor agonist, a δ-and κ–opiod Receptor antagonist and a biased ligand at μ, δ & κ–opiod Receptors, evokes antinociception with …
  245. U-50,488 H, a κ–opiod Receptor agonist, markedly prevents memory dysfunctions induced by transient cerebral ischemia in mice
  246. Butorphanol dependence increases hippocampal κ‐opiod Receptor gene expression
  247. Buprenorphine is an Antagonist at the ϰ opiod Receptor
  248. κ–opiod Receptor modulation of accumbal dopamine concentration during operant ethanol self-administration
  249. Effects of κ‐opiod Receptor stimulation in the heart and the involvement of protein kinase C
  250. Differential effects of μ-, δ-, and κ–opiod Receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat
  251. Antisense oligodeoxynucleotide to a δ-opiod Receptor selectivily blocks the spinal antinociception induced by δ-, but not μ-or κ–opiod Receptor agonists in the mouse
  252. The protective effects of κ–opiod Receptor stimulation in hypoxic pulmonary hypertension involve inhibition of autophagy through the AMPK-MTOR pathway
  253. Response of neuropeptide Y-induced feeding to μ-, δ-and κ–opiod Receptor antagonists in the neonatal chick
  254. Design of a stable cyclic peptide analgesic derived from sunflower seeds that targets the κ–opiod Receptor for the treatment of chronic abdominal pain
  255. Effect of repeated administration of TRK-820, a κ–opiod Receptor agonist, on tolerance to its antinociceptive and sedative actions
  256. Tyrosine phosphorylation of Kir3 following κ–opiod Receptor activation of p38 MAPK causes heterologous desensitization
  257. Design, synthesis and biological evaluation of aminobenzyloxyarylamide derivatives as selective κ opiod Receptor antagonists
  258. Roles of KATP channels in delayed cardioprotection and intracellular Ca2+ in the rat heart as revealed by κ‐opiod Receptor stimulation with U50,488H
  259. N-methylacetamide analog of salvinorin A: a highly potent and selective κ–opiod Receptor agonist with oral efficacy
  260. Localization of κ–opiod Receptor mRNA in neuronal subpopulations of rat sensory ganglia and spinal cord
  261. κ–opiod Receptor activation protects against myocardial ischemia-reperfusion injury via AMPK/Akt/eNOS signaling activation
  262. Analyzing interaction of μ-, δ-and κ–opiod Receptor gene variants on alcohol or drug dependence using a pattern discovery-based method
  263. … morphine administration causes differential long-lasting changes in dopaminergic neurotransmission in rat striatum without changing its δ-and κ–opiod Receptor …
  264. NMR and modeling studies of a synthetic extracellular loop II of the κ opiod Receptor in a DPC micelle
  265. Down-regulation of the tumour suppressor κ–opiod Receptor predicts poor prognosis in hepatocellular carcinoma patients
  266. Syntheses of immobilized G protein-coupled Receptor chromatographic stationary phases: characterization of immobilized μ and κ opiod Receptors
  267. Determination of sites of U50, 488H-promoted phosphorylation of the mouse κ opiod Receptor (KOPR): disconnect between KOPR phosphorylation and internalization
  268. Cloning and promoter mapping of mouse κ opiod Receptor gene
  269. Central and peripheral actions of the novel κ‐opiod Receptor agonist, EMD 60400
  270. Mouse κ–opiod Receptor mRNA differential transport in neurons
  271. Electroacupuncture relieves labour pain and influences the spinal dynorphin/κ–opiod Receptor system in rats
  272. Novel 18F-labeled κ–opiod Receptor antagonist as PET radiotracer: synthesis and in vivo evaluation of 18F-LY2459989 in nonhuman primates
  273. Effects of salvinorin A, a κ–opiod hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high κ–Receptor homology to humans
  274. … -50/Na+/H+ exchanger regulatory factor (EBP50/NHERF) blocks U50, 488H-induced down-regulation of the human κ opiod Receptor by enhancing its …
  275. κ–opiod Receptor gene as a predictor of response in a cocaine vaccine clinical trial
  276. Differential regulation of the human κ opiod Receptor by agonists: etorphine and levorphanol reduced dynorphin A-and U50, 488H-induced internalization and …
  277. Effects of the local administration of selective μ-, δ-and κ–opiod Receptor agonists on osteosarcoma-induced hyperalgesia
  278. μ‐opiod Agonist Inhibition of κ‐opiod Receptor‐Stimulated Extracellular Signal‐Regulated Kinase Phosphorylation Is Dynamin‐Dependent in C6 Glioma Cells
  279. Comparison of G-protein activation in the brain by μ-, δ-, and κ–opiod Receptor agonists in μ-opiod Receptor knockout mice
  280. Drug design and synthesis of a novel κ opiod Receptor agonist with an oxabicyclo [2.2. 2] octane skeleton and its pharmacology
  281. Distribution of κ‐opiod Receptor in the Pulmonary Artery and its Changes During Hypoxia
  282. Neuroprotective κ–opiod Receptor agonist BRL 52537 attenuates ischemia-evoked nitric oxide production in vivo in rats
  283. Cu-Catalyzed N-arylation of oxazolidinones: An efficient synthesis of the κ–opiod Receptor agonist CJ-15161
  284. Novel malonamide derivatives as potent κ opiod Receptor agonists
  285. Changes in the brain κ–opiod Receptor levels of rats in withdrawal from physical dependence upon butorphanol
  286. Effects of heat shock protein 70 activation by metabolic inhibition preconditioning or κ–opiod Receptor stimulation on Ca2+ homeostasis in rat ventricular myocytes …
  287. Identification of arodyn, a novel acetylated dynorphin A-(1− 11) analogue, as a κ opiod Receptor antagonist
  288. Effects of intrathecal κ–opiod Receptor agonist on morphine-induced itch and antinociception in mice
  289. μ but not δ and κ opiod Receptor involvement in ventrolateral orbital cortex opiod-evoked antinociception in formalin test rats
  290. Quaternary ammonium salt of U50488H, a new κ–opiod Receptor agonist, protects rat heart against ischemia/reperfusion injury
  291. Heterologous µ‐opiod Receptor adaptation by repeated stimulation of κ‐opiod Receptor: up‐regulation of G‐protein activation and antinociception
  292. In vivo and in vitro characterization of naltrindole-derived ligands at the κ–opiod Receptor
  293. Effects of morphine in rats treated chronically with U-50,488 H, a κ opiod Receptor agonist
  294. Peripheral component in the enhanced antinociceptive effect of systemic U-69,593, a κ–opiod Receptor agonist in mononeuropathic rats
  295. Changes in spinal δ and κ opiod systems in mice deficient in the A2A Receptor gene
  296. Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by μ-, δ-and κ–opiod Receptor agonists in the rat brain: Regulation by chronic morphine and opiod …
  297. Gastric effects of μ-, δ-and κ–opiod Receptor agonists on brainstem unitary responses in the neonatal rat
  298. δ, μ, and κ opiod Receptor agonists inhibit dopamine overflow in rat neostriatal slices
  299. Pharmacological properties of R-84760, a novel κ–opiod Receptor agonist
  300. Amygdalar κ–opiod Receptor-dependent upregulating glutamate transporter 1 mediates depressive-like behaviors of opiod abstinence
  301. Complete knockout of the nociceptin/orphanin FQ Receptor in the rat does not induce compensatory changes in μ, δ and κ opiod Receptors
  302. Determination of the in vivo selectivity of a new κ–opiod Receptor antagonist PET tracer 11C-LY2795050 in the rhesus monkey
  303. Highly potent and selective new diphenethylamines interacting with the κ–opiod Receptor: synthesis, pharmacology, and structure–activity relationships
  304. Analysis of the antinociceptive actions of the κ–opiod agonist enadoline (CI-977) in neonatal and adult rats: comparison to κ–opiod Receptor mRNA ontogeny
  305. Antinociceptive effect of a κ–opiod Receptor agonist that minimally crosses the blood-brain barrier (ICI 204448) in a rat model of mononeuropathy
  306. Chronic food restriction alters μ and κ opiod Receptor binding in the parabrachial nucleus of the rat: a quantitative autoradiographic study
  307. Agonist-Dependent and-Independent κ opiod Receptor phosphorylation: distinct phosphorylation patterns and different cellular outcomes
  308. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective κ‐opiod Receptor agonist
  309. κ–opiod Receptor effects of butorphanol in rhesus monkeys
  310. The association of genetic polymorphisms in the κ–opiod Receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone …
  311. Chronic cocaine increases κ‐opiod Receptor density: Lack of effect by selective dopamine uptake inhibitors
  312. N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: Selective and Nonbasic κ–opiod Receptor Ligands
  313. κ–opiod Receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naive rats
  314. Effects of κ–opiod Receptor activation on myocardium
  315. Discovery of a Highly Selective and Potent κ opiod Receptor Agonist from N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced …
  316. Up-regulation of RGS4 mRNA by opiod Receptor agonists in PC12 cells expressing cloned μ-or κ–opiod Receptors
  317. Antisense confirmation of μ-and κ–opiod Receptor mediation of morphine’s effects on body temperature in rats
  318. A highly selective κ–opiod Receptor agonist with low addictive potential and dependence liability
  319. Studies of dual promoters of mouse κ–opiod Receptor gene
  320. Enadoline, a selective κ–opiod Receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain
  321. κ–opiod Receptor stimulation reduces palmitate-induced apoptosis via Akt/eNOS signaling pathway
  322. Xylazine induced central antinociception mediated by endogenous opiods and μ-opiod Receptor, but not δ-or κ–opiod Receptors
  323. Purification and mass spectrometric analysis of the κ opiod Receptor
  324. κ–opiod Receptor stimulation improves endothelial function via Akt-stimulated NO production in hyperlipidemic rats
  325. Ischemic neuroprotection with selective κ–opiod Receptor agonist is gender specific
  326. κ–opiod Receptor as a key mediator in the regulation of appetitive 50-kHz ultrasonic vocalizations
  327. [11C]-MeJDTic: a novel radioligand for κ–opiod Receptor positron emission tomography imaging
  328. Novel signaling of dynorphin at κ–opiod Receptor/bradykinin B2 Receptor heterodimers
  329. … helical orientations among related G protein-coupled Receptors provide a novel mechanism for selectivity: studies with salvinorin A and the κ–opiod Receptor
  330. κ opiod Receptor activation in different brain regions differentially modulates anxiety-related behaviors in mice
  331. Involvement of the κ–opiod Receptor in nitrous oxide-induced analgesia in mice
  332. Dissociable effects of the κ–opiod Receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by …
  333. Synthesis of an affinity ligand (‘UPHIT’) for in vivo acylation of the κ–opiod Receptor
  334. opiods in cancer: The κ‑opiod Receptor
  335. Netrin-1 signaling regulates de novo protein synthesis of κ opiod Receptor by facilitating polysomal partition of its mRNA
  336. Differential effects of μ-, δ-and κ–opiod Receptor agonists on the discriminative stimulus properties of cocaine in rats
  337. κ–opiod Receptor stimulation increases intracellular free calcium in isolated rat ventricular myocytes
  338. κ–opiod Receptor in the nucleus is a novel prognostic factor of esophageal squamous cell carcinoma
  339. Effects of JDTic, a selective κ–opiod Receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion …
  340. Effects of Peripheral μ, δ, and κ–opiod Receptor Agonists on the Levels of Anxiety and Motor Activity of Rats
  341. Differential κ–opiod Receptor expression on mouse lymphocytes at varying stages of maturation and on mouse macrophages after selective elicitation
  342. Modulation of glutamate release by a κ–opiod Receptor agonist in rodent and primate striatum
  343. Azepinone as a conformational constraint in the design of κ–opiod Receptor agonists
  344. Anticonvulsive effects of κ‐opiod Receptor modulation in an animal model of ethanol withdrawal
  345. κ–opiod Receptor stimulation improves endothelial function in hypoxic pulmonary hypertension
  346. Plant-Derived Cyclotides Modulate κ–opiod Receptor Signaling
  347. Modulation of humoral immune response by central administration of leucine-enkephalin: Effects of μ, δ and κ opiod Receptor antagonists
  348. 2, 4-Substituted bispidines as rigid hosts for versatile applications: from κ–opiod Receptor to metal coordination
  349. Anti-arrhythmic effects of κ–opiod Receptor and its changes in ischemia and reperfusion
  350. κ–opiod Receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells
  351. μ and κ opiod Receptor distribution in the monogamous titi monkey (Callicebus cupreus): Implications for social behavior and endocrine functioning
  352. [Nα-BenzylTyr,cyclo(d-Asp5,Dap8)]- dynorphin A-(1−11)NH2 Cyclized in the “Address” Domain Is a Novel κ–opiod Receptor Antagonist
  353. Effects of U-50,488 H, a κ–opiod Receptor agonist, on the learned helplessness model of depression in mice
  354. The selective κ–opiod Receptor agonist U50, 488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates
  355. Evidence for coupling of the κ opiod Receptor to brain GTPase
  356. A novel κ–opiod Receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice
  357. κ–opiod Receptor signals through Src and focal adhesion kinase to stimulate c-Jun N-terminal kinases in transfected COS-7 cells and human monocytic THP-1 cells
  358. Ligands regulate cell surface level of the human κ opiod Receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement …
  359. Reactive oxygen species (ROS) generation is stimulated by κ opiod Receptor activation through phosphorylated c-Jun N-terminal kinase and inhibited by p38 …
  360. The effect of activated κ–opiod Receptor (κ-OR) on the role of calcium sensing Receptor (CaSR) in preventing hypoxic pulmonary hypertension development
  361. κ–opiod Receptor mediates the antinociceptive effect of nitrous oxide in mice
  362. Retinoic acid-induced chromatin remodeling of mouse κ opiod Receptor gene
  363. Antagonism of κ opiod Receptor in the nucleus accumbens prevents the depressive-like behaviors following prolonged morphine abstinence
  364. κ–opiod Receptor model in a phospholipid bilayer: Molecular dynamics simulation
  365. Cardioprotection with κ–opiod Receptor stimulation is associated with a slowing of cross-bridge cycling
  366. Influence of asimadoline, a new κ‐opiod Receptor agonist, on tubular water absorption and vasopressin secretion in man
  367. Peripheral neuronal nitric oxide synthase activity mediates the antinociceptive effect of Crotalus durissus terrificus snake venom, a δ-and κ–opiod Receptor agonist
  368. The adrenergic Receptor agonist, clonidine, potentiates the anti‐parkinsonian action of the selective κ‐opiod Receptor agonist, enadoline, in the monoamine‐depleted …
  369. Amygdala dynorphin/κ opiod Receptor system modulates depressive-like behavior in mice following chronic social defeat stress
  370. RGS2 and RGS4 proteins: New modulators of the κ–opiod Receptor signaling
  371. Disability of development of tolerance to morphine and U-50,488 H, a selective κ–opiod Receptor agonist, in neuropathic pain model mice
  372. … effect of a benzilidine-cyclohexanone analogue on a mouse model of chronic constriction injury-induced neuropathic pain: Participation of the κ–opiod Receptor and …
  373. κ–opiod regulation of thymocyte IL-7 Receptor and CC chemokine Receptor 2 expression
  374. Synthesis and Pharmacological Evaluation of Fluorinated Quinoxaline‐Based κ‐opiod Receptor (KOR) Agonists Designed for PET Studies
  375. Variants of κ–opiod Receptor gene and mRNA in alcohol-preferring and alcohol-avoiding mice
  376. Differentiation of δ, μ, and κ opiod Receptor agonists based on pharmacophore development and computed physicochemical properties
  377. The anticonvulsant action of CI-977, a selective κ–opiod Receptor agonist: a possible involvement of the glycine/NMDA Receptor complex
  378. A novel signaling pathway of nitric oxide on transcriptional regulation of mouse κ opiod Receptor gene
  379. … to confer cardioprotection and to increase the expression of heat-shock protein 70 by preconditioning with a κ–opiod Receptor agonist during ischaemia and …
  380. Effect of μ and κ opiod Receptor agonists on rat plasma corticosterone levels
  381. Activity of the δ-opiod Receptor is partially reduced, whereas activity of the κ–Receptor is maintained in mice lacking the μ-Receptor
  382. … neurotoxicity in mice via upregulation of dynorphin-mediated κ–opiod Receptor and downregulation of substance P-mediated neurokinin 1 Receptor
  383. Tyrosine phosphorylation of the κ–opiod Receptor regulates agonist efficacy
  384. Current κ opiod Receptor ligands and discovery of a new molecular scaffold as a κ opiod Receptor antagonist using pharmacophore-based virtual screening
  385. … of GEC1 protein and γ-aminobutyric acid type A (GABAA) Receptor-associated protein (GABARAP), two microtubule-associated proteins, on κ opiod Receptor …
  386. Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ–opiod Receptor Agonists with Anti-Inflammatory Activity in Vivo
  387. Discovery of peripheral κ–opiod Receptor agonists as novel analgesics
  388. GEC1-κ opiod Receptor binding involves hydrophobic interactions: GEC1 has chaperone-like effect
  389. Molecular modeling study of the differential ligand–Receptor interaction at the μ, δ and κ opiod Receptors
  390. Study of the involvement of K+ channels in the peripheral antinociception of the κ–opiod Receptor agonist bremazocine
  391. Regulation of mouse κ opiod Receptor gene expression by different 3′-untranslated regions and the effect of retinoic acid
  392. κ–opiod Receptor is involved in the cardioprotection induced by exercise training
  393. The G‐protein biased partial κ opiod Receptor agonist 6′‐GNTI blocks hippocampal paroxysmal discharges without inducing aversion
  394. … behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel κ–opiod Receptor agonist nalfurafine hydrochloride
  395. The μ-opiod activity of κ–opiod Receptor agonist compounds in the guinea pig ileum
  396. Cellular distribution of the mRNA for the κ–opiod Receptor in the human neocortex: a non-isotopic in situ hybridization study
  397. In Vivo Modulation of Post‐Spike Excitability in Vasopressin Cells by κ‐opiod Receptor Activation
  398. Topical κ‐opiod Receptor agonist asimadoline improves dermatitis in a canine model of atopic dermatitis
  399. Lack of effect of γ-hydroxybutyrate on μ, δ and κ opiod Receptor binding
  400. Role of κ—opiod Receptor in Hypoxic Pulmonary Artery Hypertension and Its Underlying Mechanism
  401. Treatment of cocaine craving with as-needed nalmefene, a partial κ opiod Receptor agonist: first clinical experience
  402. G protein coupled Receptor kinase-2 upregulation causes κ–opiod Receptor desensitization in diabetic heart
  403. Identity of the putative δ1-opiod Receptor as a δ–κ heteromer in the mouse spinal cord
  404. U-50488H, a selective κ–opiod Receptor agonist, improves carbon monoxide-induced delayed amnesia in mice
  405. A population pharmacokinetic and pharmacodynamic study of a peripheral κ–opiod Receptor agonist CR665 and oxycodone
  406. Protein kinase C-ε is a trigger of delayed cardioprotection against myocardial ischemia of κ–opiod Receptor stimulation in rat ventricular myocytes
  407. μ-and κ–opiod Receptor agonists produce peripheral inhibition of neurogenic plasma extravasation in rat skin
  408. A highly selective κ–opiod Receptor agonist, CI-977, reduces excitatory synaptic potentials in the rat locus coeruleus in vitro
  409. κ–opiod Receptor inhibition of calcium oscillations in spinal cord neurons
  410. A select set of opiod ligands induce up-regulation by promoting the maturation and stability of the rat κ–opiod Receptor in human embryonic kidney 293 cells
  411. Synthesis, biological evaluation, and Receptor docking simulations of 2-[(acylamino) ethyl]-1, 4-benzodiazepines as κ–opiod Receptor agonists endowed with …
  412. Modulation of the Neurotoxic Effects of Methamphetamine by the Selective κ‐opiod Receptor Agonist U69593
  413. Investigation of the μ‐and κ‐opiod Receptor activation by eight new synthetic opiods using the [35S]‐GTPγS assay: U‐47700, isopropyl U‐47700, U‐49900, U …
  414. Novel κ–opiod Receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation
  415. Activation of the κ–opiod Receptor in Caco-2 cells decreases interleukin-8 secretion
  416. Inhibitory and excitatory effects of μ-, δ-, and κ–opiod Receptor activation on breathing in awake turtles, Trachemys scripta
  417. Neurofilament proteins and cAMP pathway in brains of μ-, δ-or κ–opiod Receptor gene knock-out mice: effects of chronic morphine administration
  418. Design, synthesis and biological evaluation of N-hydroxy-aminobenzyloxyarylamide analogues as novel selective κ opiod Receptor antagonists
  419. κ opiod Receptor interacts with Na+/H+-exchanger regulatory factor-1/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na+ …
  420. Stress-induced epigenetic regulation of κ–opiod Receptor gene involves transcription factor c-Myc
  421. κ–opiod Receptor stimulation inhibits growth of neonatal rat ventricular myocytes
  422. Synthesis and evaluation of novel peripherally restricted κ–opiod Receptor agonists
  423. The novel κ–opiod Receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice
  424. Butorphanol alleviates lipopolysaccharide‑induced inflammation and apoptosis of cardiomyocytes via activation of the κ‑opiod Receptor
  425. The κ–opiod Receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety
  426. Functional evidence for interaction between prostaglandin EP3 and κ–opiod Receptor pathways in tactile pain induced by human immunodeficiency virus type-1 (HIV-1 …
  427. Arylacetamide κ–opiod Receptor agonists produce a tonic-and use-dependent block of tetrodotoxin-sensitive and-resistant sodium currents in colon sensory neurons
  428. Potentiation of κ–opiod Receptor agonist-induced analgesia and hypothermia by fluoxetine
  429. Apparent efficacy of κ–opiod Receptor ligands on serum prolactin levels in rhesus monkeys
  430. Blockade of the morphine-induced increase in turnover of dopamine on the mesolimbic dopaminergic system by κ–opiod Receptor activation in mice
  431. Synthesis and absolute configuration of optically pure enantiomers of a ϰ‐opiod Receptor selective agonist
  432. Na+ ions and Gpp (NH) p selectively inhibit agonist interactions at μ-and κ–opiod Receptor sites in rabbit and guinea-pig cerebellum membranes
  433. Effects of μ-, δ-and κ–opiod Receptor agonists on methamphetamine-induced self-injurious behavior in mice
  434. Early ontogeny of κ–opiod Receptor regulation of prolactin secretion in the rat
  435. Separation of κ–opiod Receptor subtype from frog brain
  436. Transcriptional regulation of the major HIV‐1 coReceptor, CXCR4, by the κ opiod Receptor
  437. κ–opiod Receptor stimulation inhibits cardiac hypertrophy induced by β1-adrenoceptor stimulation in the rat
  438. The effect of κ–opiod Receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons
  439. The role of phosphodiesterase in mediating the effect of protein kinase C on cyclic AMP accumulation upon κ–opiod Receptor stimulation in the rat heart
  440. Synthesis and pharmacology of a novel κ opiod Receptor (KOR) agonist with a 1, 3, 5-trioxazatriquinane skeleton
  441. Mitochondrial dysfunction and apoptosis are attenuated on κ–opiod Receptor activation through AMPK/GSK-3β pathway after myocardial ischemia and reperfusion
  442. Expression of κ–opiod Receptor mRNA in human peripheral blood lymphocytes and the relationship between its expression and the inflammatory changes in …
  443. Impaired [Ca2+]i and pHiresponses to κ–opiod Receptor stimulation in the heart of chronically hypoxic rats
  444. Discovery of N-methyltetrahydroprotoberberines with κ–opiod Receptor agonists-opiod Receptor agonist activities from corydalis yanhusuo WT Wang by using two …
  445. Spontaneous excitatory currents and κ–opiod Receptor inhibition in dentate gyrus are increased in the rat pilocarpine model of temporal lobe epilepsy
  446. Nalfurafine hydrochloride, a selective κ opiod Receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys
  447. … 17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6β-[(4′-pyridyl) carboxamido] morphinan (NAP) derivatives as μ/κ opiod Receptor dual selective ligands
  448. Regulation of κ–opiod Receptor mRNA level by cyclic AMP and growth factors in cultured rat glial cells
  449. Structural determinants of diphenethylamines for interaction with the κ opiod Receptor: Synthesis, pharmacology and molecular modeling studies
  450. Baicalein protects chicken embryonic cardiomyocyte against hypoxia–reoxygenation injury via μ-and δ-but not κ–opiod Receptor signaling
  451. Effects of U-69,593, a κ–opiod Receptor agonist, on carrageenin-induced peripheral oedema and Fos expression in the rat spinal cord
  452. κ–opiod Receptor potentiates apoptosis via a phospholipase C pathway in the CNE2 human epithelial tumor cell line
  453. Cholecystokinin octapeptide reverses the κ–opiod–Receptor-mediated depression of calcium current in rat dorsal root ganglion neurons
  454. κ–opiod Receptor antagonism reverses heroin withdrawal-induced hyperalgesia in male and female rats
  455. Hypericum perforatum inhibits the binding of μ-and κ–opiod Receptor expressed with the Semliki Forest virus system
  456. Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac κ–opiod Receptor stimulation
  457. Effects of acute agonist treatment on subcellular distribution of κ opiod Receptor in rat spinal cord
  458. κ–opiod Receptor modulation of GABAergic inputs onto ventrolateral periaqueductal gray dopamine neurons
  459. Arylacetamide κ opiod Receptor agonists with reduced cytochrome P450 2D6 inhibitory activity
  460. µ-and κ–opiod Receptor activation in the dorsal periaqueductal grey matter differentially modulates panic-like behaviours induced by electrical and chemical …
  461. κ–opiod Receptor stimulation inhibits augmentation of Ca2+ transient and hypertrophy induced by isoprenaline in neonatal rat ventricular myocytes—Role of …
  462. Effects of ibogaine on the development of tolerance to antinociceptive action of μ-, δ-and κ–opiod Receptor agonists in mice
  463. Effect of μ, δ and κ opiod Receptor agonists on a reactive oxygen species mediated model of skin inflammation
  464. κ–opiod Receptor agonist-induced prolactin release in primates is blocked by dopamine D2-like Receptor agonists
  465. Gi1 and GoA differentially determine kinetic efficacies of agonists for κ–opiod Receptor
  466. The NMDA Receptor antagonist MK-801 differentially modulates μ and κ opiod actions in spinal cord in vitro
  467. The κ–opiod Receptor expressed on the mouse lymphoma cell line R1. 1 contains a sulfhydryl group at the binding site
  468. … to a δ-opiod Receptor messenger rna selectively blocks the antinociception induced by intracerebroventricularly administered δ-, but not μ-, ϵ-, or κ–opiod Receptor …
  469. Conformationally restricted κ–opiod Receptor agonists: Synthesis and pharmacological evaluation of diastereoisomeric and enantiomeric decahydroquinoxalines
  470. Effects of ibogaine and noribogaine on the antinociceptive action of μ-, δ-and κ–opiod Receptor agonists in mice
  471. Dual regulation by μ, δ and κ opiod Receptor agonists of K+ conductance of DRG neurons and neuroblastoma× DRG neuron hybrid F11 cells
  472. Decrease of κ–opiod Receptor mRNA level in ventral tegmental area of male mice after repeated experience of aggression
  473. Effect of U50, 488H, a κ–opiod Receptor agonist on myocardial α-and β-myosin heavy chain expression and oxidative stress associated with isoproterenol-induced …
  474. Generalization of NMDA-Receptor antagonists to the discriminative stimulus effects of κ–opiod Receptor agonists U-50,488 H, but not TRK-820 in rats
  475. Effect of κ–opiod Receptor agonists on morphine analgesia in morphine-naive and morphine-tolerant rats
  476. κ–opiod Receptor activation prevents against arrhythmias by preserving Cx43 protein via alleviation of intracellular calcium
  477. κ–opiod Receptor stimulation induces arrhythmia in the isolated rat heart via the protein kinase C/Na+–H+ exchange pathway
  478. κ–opiod Receptor agonist protects against ischemic reduction of 2-deoxyglucose uptake in morphine-tolerant rats
  479. Endomorphin-1 Discriminates the μ-opiod Receptor From the δ-and κ–opiod Receptors by Recognizing the Difference in Multiple Regions
  480. Efficacy and safety of a new κ–opiod Receptor agonist for the treatment of uremic pruritus
  481. Effect of dizocilpine (MK-801) on analgesia and tolerance induced by U-50,488 H, a κ–opiod Receptor agonist, in the mouse
  482. Effects of spiradoline mesylate, a selective κ–opiod–Receptor agonist, on the central dopamine system with relation to mouse locomotor activity and analgesia
  483. Mechanisms involved in the hypotensive effect of a κ–opiod Receptor agonist in hypertensive rats
  484. Promoter activity of mouse κ opiod Receptor gene in transgenic mouse
  485. Peripheral administration of κ–opiod Receptor antagonist stimulates gonadotropin-releasing hormone pulse generator activity in ovariectomized, estrogen-treated …
  486. Efficient synthesis of the κ–opiod Receptor agonist CJ-15,161: four stereospecific inversions at a single aziridinium stereogenic center
  487. Induction of the mouse κ–opiod Receptor gene by retinoic acid in P19 cells
  488. PRO‐AND ANTI‐ARRHYTHMIC EFFECTS OF A κ opiod Receptor AGONIST: A MODEL FOR THE BIPHASIC ACTION OF A LOCAL HORMONE IN THE HEART
  489. κ opiod Receptor stimulation of [35S] GTPγS binding in guinea pig brain
  490. Chronic U50, 488H abolishes inositol 1, 4, 5-trisphosphate and intracellular Ca2+ elevations evoked by κ–opiod Receptor in rat myocytes
  491. … M-Substituted N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaine as a Selective, Potent, and Orally Active κ–opiod Receptor Agonist with an …
  492. The κ–opiod Receptor antagonist JDTic decreases ethanol intake in alcohol-preferring AA rats
  493. Central monoaminergic mechanisms in mice and analgesic activity of spiradoline mesylate, a selective κ–opiod Receptor agonist
  494. Prospects of using of κ–opiod Receptor agonists U-50,488 and ICI 199,441 for improving heart resistance to ischemia/reperfusion
  495. Contralateral, ipsilateral and bilateral treatments with the κ–opiod Receptor agonist U-50,488 H in mononeuropathic rats
  496. Diminution of contractile response by κ–opiod Receptor agonists in isolated rat ventricular cardiomyocytes is mediated via a pertussis toxin-sensitive G protein
  497. [Pro3]Dyn A(1−11)-NH2:  A Dynorphin Analogue with High Selectivity for the κ opiod Receptor
  498. Analogs of the κ opiod Receptor antagonist arodyn cyclized by ring-closing metathesis retain κ opiod Receptor affinity, selectivity and κ opiod Receptor antagonism
  499. N-substituted 4β-methyl-5-(3-hydroxyphenyl)-7α-amidomorphans are potent, selective κ opiod Receptor antagonists
  500. Differential effects of μ-opiod, δ-opiod and κ–opiod Receptor agonists on dopamine Receptor agonist-induced climbing behavior in mice
  501. Coupling of the cloned rat κ–opiod Receptor to adenylyl cyclase is dependent on Receptor expression
  502. The amygdala mediates the impairing effect of the selective κ–opiod Receptor agonist U-50,488 on memory in CD1 mice
  503. κ–opiod Receptor agonist inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion and CXCR4 expression on CD4+ lymphocytes
  504. Behavioral characterization of κ opiod Receptor agonist spiradoline and cannabinoid Receptor agonist CP55940 mixtures in rats
  505. The κ–opiod Receptor agonist U50, 488H induces acute physical dependence in guinea-pigs
  506. Antagonism of the morphine-induced Straub tail reaction by κ–opiod Receptor activation in mice
  507. Activation of κ–opiod Receptor by U50, 488H improves vascular dysfunction in streptozotocin-induced diabetic rats
  508. Comparative effects of selective κ–opiod Receptor agonists on dopamine levels in the dorsal caudate of freely moving rats
  509. Modification of κ–opiod Receptor agonist-induced antinociception by diabetes in the mouse brain and spinal cord
  510. Process research and scale-up of the κ–opiod Receptor agonist CJ-15,161 drug candidate
  511. Participation of dorsal periaqueductal gray 5-HT1A Receptors in the panicolytic-like effect of the κ–opiod Receptor antagonist Nor-BNI
  512. κ‐opiod Receptor‐mediated enhancement of the hyperpolarization‐activated current (Ih) through mobilization of intracellular calcium in rat nucleus raphe magnus
  513. μ-, δ-and κ–opiod Receptor agonists do not alter the discriminative stimulus effects of cocaine or d-amphetamine in rats
  514. κ opiod Receptor 1 single nucleotide polymorphisms were associated with the methadone dosage
  515. Selective natural κ opiod and cannabinoid Receptor agonists with a potential role in the treatment of gastrointestinal dysfunction-Analogues of salvinorin A, an …
  516. κ–opiod Receptor antagonism improves recovery from myocardial stunning in chronically instrumented dogs
  517. Replacing a Palatable High-Fat Diet with a Low-Fat Alternative Heightens κ–opiod Receptor Control over Nucleus Accumbens Dopamine
  518. Serotonergic and GABAergic neurons in the medial rostral ventral medulla express κ–opiod Receptor immunoreactivity
  519. Combination of cyclohexane and piperazine based κ–opiod Receptor agonists: synthesis and pharmacological evaluation of trans, trans-configured …
  520. μ-but not δ-and κ–opiod Receptor mediates the nucleus submedius interferon-α-evoked antinociception in the rat
  521. Specific κ opiod Receptor agonists
  522. Precipitated κ–opiod Receptor agonist withdrawal increases glutamate in rat locus coeruleus
  523. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the κ‐opiod Receptor
  524. N-[18F]-FluoropropylJDTic for κ–opiod Receptor PET imaging: Radiosynthesis, pre-clinical evaluation, and metabolic investigation in comparison with parent JDTic
  525. Postsynaptic and extrasynaptic localization of κ–opiod Receptor in selected brain areas of young rat and chick using an anti-Receptor monoclonal antibody
  526. The κ–opiod Receptor antagonist nor-BNI inhibits cocaine and amphetamine, but not cannabinoid (WIN 52212-2), abstinence-induced withdrawal in planarians: An …
  527. Role of protein kinase C‐epsilon in the development of κ‐opiod Receptor tolerance to U50, 488H in rat ventricular myocytes
  528. OFQ reverses the κ–opiod Receptor-mediated depression of calcium current in rat dorsal root ganglion neurons
  529. A Bivalent Ligand (KDAN-18) Containing δ-Antagonist and κ-Agonist Pharmacophores Bridges δ2 and κ1 opiod Receptor Phenotypes
  530. p38 mitogen-activated protein kinase activation in amygdala mediates κ opiod Receptor agonist U50, 488H-induced conditioned place aversion
  531. Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ–opiod Receptor agonists
  532. … Receptor Docking Simulations of 2-[(Acylamino)ethyl]-1,4-benzodiazepines as Novel Tifluadom-like Ligands with High Affinity and Selectivity for κ–opiod Receptors
  533. The κ–opiod Receptor Agonist U-50488 Blocks Ca2+ Channels in a Voltage-and G Protein–Independent Manner in Sensory Neurons
  534. Chemical function-based pharmacophore generation of selective κ–opiod Receptor agonists by catalyst and phase
  535. κ‑opiod Receptor agonists may alleviate intestinal damage in cardiopulmonary bypass rats by inhibiting the NF‑κB/HIF‑1α pathway
  536. P38: The link between the κ–opiod Receptor and dysphoria
  537. Attenuation of the antinociceptive action of the selective κ–opiod Receptor agonist, U-50,488 H by ICS-205-930
  538. Synthesis and biological evaluation of dibenz [b, f][1, 5] oxazocine derivatives for agonist activity at κ–opiod Receptor
  539. Species differences in the effects of the κ–opiod Receptor antagonist zyklophin
  540. κ‐opiod Receptor binding varies inversely with tumor grade in human gliomas
  541. Differential effects of LY235959, a competitive antagonist of the NMDA Receptor on κ–opiod Receptor agonist induced responses in mice and rats
  542. Activation of κ‐opiod Receptor Exerts the Glucose‐Homeostatic Effect in Streptozotocin‐Induced Diabetic Mice
  543. Activation of κ–opiod Receptor inhibits inflammatory response induced by sodium palmitate in human umbilical vein endothelial cells
  544. Potent inhibition of alcohol self-administration in alcohol-preferring rats by a κ–opiod Receptor antagonist
  545. How does agonist and antagonist binding lead to different conformational ensemble equilibria of the κ–opiod Receptor: Insight from long-time gaussian accelerated …
  546. Differential time course of effects of κ–opiod agonist treatment on dynorphin a levels and κ–opiod Receptor density
  547. … combinations with intrathecal BRL52537 (κ–opiod agonist), pregabalin (calcium channel modulator), AF 353 (P2X3 Receptor antagonist), and A804598 (P2X7 Receptor …
  548. κ–opiod Receptor agonists improve pirenzepine-induced disturbance of spontaneous alternation performance in the mouse
  549. Differential antagonism of the rate-decreasing effects of κ–opiod Receptor agonists by naltrexone and norbinaltorphimine
  550. The κ–opiod Receptor agonist asimadoline inhibits epithelial transport in mouse trachea and colon
  551. Limbic brain structures are important sites of κ–opiod Receptor-mediated actions in the rat: a [14C]-2-deoxyglucose study
  552. κ opiod Receptor Agonist Inhibits Myocardial Injury in Heart Failure Rats through Activating Nrf2/HO-1 Pathway and Regulating Ca2+-SERCA2a
  553. Study of μ-and δ-opiod Activities in Agents with Various κ–Receptor Selectivity
  554. Isolation and Chemical Modification of Clerodane Diterpenoids from Salvia Species as Potential Agonists at the κ‐opiod Receptor
  555. Kinetic Modeling and Test–Retest Reproducibility of 11C-EKAP and 11C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the κ–opiod Receptor in Humans
  556. Syntheses of potential metabolites of a potent κ–opiod Receptor agonist, TRK-820
  557. Pertussis and cholera toxins modulate κ–opiod Receptor agonists-induced hypothermia and gut inhibition
  558. κ–opiod Receptor antisense oligonucleotide injected into rat hippocampus causes hypertension
  559. Recent development and potential use of µ‐and κ‐opiod Receptor ligands in positron emission tomography studies
  560. Reversion of muscarinic autoReceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1–13), an endogenous κ–opiod Receptor …
  561. Effectiveness of nalbuphine, a κ‐opiod Receptor agonist and μ‐opiod Receptor antagonist, in the inhibition of INa, IK(M), and IK(erg) unlinked to interaction with …
  562. κ–opiod Receptor-mediated analgesia: hotplate temperature and sex differences
  563. κ–opiod Receptor stimulation alleviates rat vascular smooth muscle cell calcification via PFKFB3-lactate signaling
  564. Amino acid conjugates as κ opiod Receptor agonists
  565. Syntheses of 10-Oxo, 10α-Hydroxy, and 10β-Hydroxy Derivatives of a Potent κ–opiod Receptor Agonist, TRK-820
  566. Involvement of κ‐opiod Receptors in peripheral response to nerve stimulation in κ‐opiod Receptor knockout mice
  567. Focal κ–opiod Receptor-mediated dependence and withdrawal in the nucleus paragigantocellularis
  568. Chronic κ–opiod Receptor antagonism delays the rise in blood pressure in spontaneously hypertensive rats
  569. Differential efficacies of κ agonists to induce homologous desensitization of human κ opiod Receptor
  570. Age-dependent effects of κ–opiod Receptor stimulation on cocaine-induced stereotyped behaviors and dopamine overflow in the caudate–putamen: an in vivo …
  571. The function of calcineurin and ERK1/2 signal in the antihypertrophic effects of κ–opiod Receptor stimulation on myocardial hypertrophy induced by isoprenaline
  572. κ–opiod Receptor mediated antinociception in rats is dependent on the functional state of dihydropyridine-sensitive calcium channels
  573. N-Alkylated derivatives of [d-Pro10] dynorphin A-(1-11) are high affinity partial agonists at the cloned rat κ–opiod Receptor
  574. Neurokinin 1 Receptor signaling mediates sex differences in μ and κ opiod-induced enhancement of contact hypersensitivity
  575. Molecular simulation of dynorphin A-(1− 10) binding to extracellular loop 2 of the κ–opiod Receptor. A model for Receptor activation
  576. Effects of peripheral and spinal κ–opiod Receptor stimulation on the exercise pressor reflex in decerebrate rats
  577. κ–opiod Receptor agonist inhibits the cholera toxin-sensitive G protein in the heart
  578. Direct detection of neuropeptide dynorphin A binding to the second extracellular loop of the κ opiod Receptor using a soluble protein scaffold
  579. Inhibition of elevated arginine vasopressin secretion in response to osmotic stimulation and acute haemorrhage by U‐62066E, a κ‐opiod Receptor agonist
  580. Renal responses to the κ–opiod–Receptor agonist U-50488H in conscious lambs
  581. Tonic modulation of neurotransmitter release in the guinea-pig myenteric plexus: effect of μ and κ opiod Receptor blockade and of chronic sympathetic denervation
  582. 14-3-3ζ Protein regulates anterograde transport of the human κ–opiod Receptor (hKOPR)
  583. κ–opiod Receptor agonist U50, 488H attenuates myocardial ischemia-reperfusionvia modulating Toll-like Receptor 4/nuclear factor-κB signaling in rat
  584. Central antinociception induced by µ‐opiod Receptor agonist morphine, but not δ‐ or κ‐, is mediated by cannabinoid CB1 Receptor
  585. Dynorphin A (1–8) inhibits oxidative stress and apoptosis in MCAO rats, affording neuroprotection through NMDA Receptor and κ–opiod Receptor channels
  586. Indirect dopamine agonists augment the locomotor activating effects of the κ‐opiod Receptor agonist U‐50,488 in preweanling rats
  587. Fentanyl combined with butorphanol protects myocardial ischemia/reperfusion injury via κ–opiod Receptor-mediated Nrf2-ARE signaling
  588. The stereoselective κ–opiod Receptor antagonist Mr 2266 does not exhibit stereoselectivity as an antagonist at the orphan opiod (ORL1) Receptor
  589. Role of dopamine D1 Receptors for κ–opiod–mediated locomotor activity and antinociception during the preweanling period: a study using D1 Receptor knockout mice
  590. A cell-based, high-throughput homogeneous time-resolved fluorescence assay for the screening of potential κ–opiod Receptor agonists
  591. Novel phenylamino acetamide derivatives as potent and selective κ opiod Receptor agonists
  592. Dog cerebral cortex contains μ-, δ-and κ–opiod Receptors at different densities: apparent lack of evidence for subtypes of the κ–Receptor using selective radioligands
  593. Sensitization of the adenylyl cyclase system in cloned κ–opiod Receptor-transfected cells following sustained agonist treatment: a chimeric study using G protein αi2/αq …
  594. Response of rat globus pallidus neurons to microiontophoretically applied μ and κ opiod Receptor agonists
  595. Ultrasonic vocalizations of preweanling rats: involvement of both α2-adrenoceptor and κ–opiod Receptor systems
  596. Suppression of Acute Herpetic Pain-Related Responses by the κ–opiod Receptor Agonist (-)-17-Cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6β-[N-methyl-3 …
  597. Evidence of involvement of the nNOS and the κ–opiod Receptor in the same intracellular network of the rat periaqueductal gray that controls morphine tolerance and …
  598. Effects of acute and repeated morphine treatment on κ–opiod Receptor protein levels in mesocorticolimbic system
  599. The κ–opiod Receptor agonist U-69593 prevents cocaine-induced phosphorylation of DARPP-32 at Thr34 in the rat brain
  600. Preparation and evaluation of some hydrophilic phenylacetyl-piperazines as peripherally selective κ–opiod Receptor agonists
  601. κ‐opiod Receptor Agonists Differentially Affect the Release of Neurohypophysial Hormones
  602. Mechanism of direct Cav2. 2 channel block by the κ–opiod Receptor agonist U50488H
  603. Synthesis and pharmacological evaluation of conformationally restricted κ–opiod Receptor agonists
  604. κ–opiod Receptor Agonist Ameliorates Postoperative Neurocognitive Disorder by Activating the Ca2+/CaMKII/CREB Pathway
  605. Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective κ–opiod Receptor antagonist
  606. Profiles of the antinociceptive effect of R-84760, a selective κ–opiod Receptor agonist, in the formalin test in mice
  607. Effect of ICI197067, a κ–opiod Receptor agonist, spinally on Aδ and C reflexes and intracerebrally on respiration
  608. Effect of chronic administration of U-50,488 H, a κ–opiod Receptor agonist, on central dopamine D2 Receptors of the rat
  609. Identification of κ-and δ-opiod Receptor transcripts in immune cells
  610. Effects of κ–opiod Receptor agonists on stimulated phosphoinositide hydrolysis in rat kidney
  611. κ‑opiod Receptor agonist, U50488H, inhibits pyroptosis through NLRP3 via the Ca2+/CaMKII/CREB signaling pathway and improves synaptic plasticity in …
  612. Involvement of dopamine D2 Receptor signal transduction in the discriminative stimulus effects of the κ–opiod Receptor agonist U-50,488 H in rats
  613. Acidosis antagonizes intracellular calcium response to κ–opiod Receptor stimulation in the rat heart
  614. Region-dependent G-protein activation by κ–opiod Receptor agonists in the mouse brain
  615. The selective κ–opiod Receptor antagonist JDTic attenuates the alcohol deprivation effect in rats
  616. Expression of μ-and κ-, but not δ-, opiod Receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats
  617. Negative modulation of spinal κ–opiod Receptor-mediated antinociception by the µ-opiod Receptor at selective doses of (−)-pentazocine
  618. Gastric acid secretion by central injection of dynorphin A-(1–17), an endogenous ligand of κ–opiod Receptor, in urethane-anesthetized rats
  619. Interaction of Extracellular Loop II of κ–opiod Receptor (196–228) with opiod Peptide Dynorphin in Membrane Environments as Revealed by Solid State Nuclear …
  620. The κ–opiod Receptor agonist, U50, 488H, exerts antidystonic activity in a mutant hamster model of generalized dystonia
  621. Design, synthesis and biological evaluation of novel tetrahydroisoquinoline quaternary derivatives as peripheral κ–opiod Receptor agonists
  622. κ‑opiod Receptor agonist U50488H attenuates postoperative cognitive dysfunction of cardiopulmonary bypass rats through the PI3K/AKT/Nrf2/HO‑1 pathway
  623. Stimulatory effects of centrally injected κ–opiod Receptor agonists on gastric acid secretion in urethane-anesthetized rats
  624. Biphasic effect of a κ–opiod Receptor agonist on plasma oxytocin levels in rats
  625. Use of Receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the κ opiod Receptor
  626. κ–opiod Receptor stimulation increases the expression of Na+-H+ exchange gene in the heart
  627. Synthesis and evaluation of κ–opiod Receptor agonistic activity and antinociceptive effect of novel morphine analogues, 7α-phenyl-6α, 14α-endo-etheno …
  628. [125I] Dynorphin (1–8) produces a similar pattern of κ–opiod Receptor labelling to [3H] dynorphin (1–8) and [3H] etorphine in guinea pig brain: A quantitative …
  629. Development of κ opiod Receptor agonists by focusing on phenyl substituents of 4-dimethylamino-3-phenylpiperidine derivatives: structure–activity relationship study …
  630. Synergistic opiod inhibition of colonic Cl− secretion by κ–opiod Receptor agonism plus μ-opiod Receptor antagonism
  631. Pharmacological Characterization of Human κ/μ opiod Receptor Chimeras that Retain High Affinity for Dynorphin A
  632. Involvement of glutamate and γ‐amino‐butyric acid Receptor systems on gastric acid secretion induced by activation of κ‐opiod Receptors in the central nervous …
  633. Receptor-mediated activation of G-proteins by κ opiod agonists in frog (Rana esculenta) brain membranes
  634. Enantiomers of 2‐[(Acylamino) ethyl]‐1, 4‐benzodiazepines, Potent ligands of κ‐opiod Receptor: Chiral chromatographic resolution, configurational assignment, and …
  635. Identification of an opiod κ Receptor Subtype-Selective N-Substituent for (+)-(3R,4R)-Dimethyl-4-(3-hydroxyphenyl)piperidine
  636. Plasticity of signaling by spinal estrogen Receptor α, κ–opiod Receptor, and metabotropic glutamate Receptors over the rat reproductive cycle regulates spinal …
  637. Differential effects of acute and repeated morphine treatment on κ–opiod Receptor mRNA levels in mesocorticolimbic system
  638. Direct evidence for the up‐regulation of spinal µ‐opiod Receptor function after repeated stimulation of κ‐opiod Receptors in the mouse
  639. Activation of c-fos mRNA in the brain by the κ–opiod Receptor agonist enadoline and the NMDA Receptor antagonist dizocilpine
  640. κ opiod Receptor-Dynorphin Signaling in the Central Amygdala Regulates Conditioned Threat Discrimination and Anxiety
  641. Drug–drug interactions of a novel κ–opiod Receptor agonist, nalfurafine hydrochloride, involving the P-glycoprotein
  642. A Subtype of κ‐opiod Receptor Mediates Inhibition of High‐Affinity GTPase Inherent in Gi1 in Guinea Pig Cerebellar Membranes
  643. Effects of κ-and μ-opiod Receptor agonists on Ca2+ channels in neuroblastoma cells: involvement of the orphan opiod Receptor
  644. Potency enhancement of the κ–opiod Receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif
  645. κ–opiod Receptor-mediated thermonociceptive mechanisms in streptozotocin diabetes
  646. Discovery of highly selective κ–opiod Receptor agonists: 10α-Hydroxy TRK-820 derivatives
  647. … -[2-(1-pyrrolidinyl)-cyclohexyl] benzeneacetamide] Induces Internalization and Down-Regulation of the Human, but not the Rat, κ–opiod Receptor: Structural Basis for …
  648. Dynorphin regulates the phagocytic activity of splenic phagocytes in wall lizards: involvement of a κ–opiod Receptor-coupled adenylate-cyclase–cAMP–PKA pathway
  649. Nonspecific Effects of the Selective κ–opiod Receptor AgonistU-50,488 H on Dopamine Uptake and Release in PC12 Cells
  650. Mixed κ/μ opiod Receptor agonists: the 6β-naltrexamines
  651. Effects of R-84760, a selective κ–opiod Receptor agonist, on nociceptive reflex in isolated neonatal rat spinal cord
  652. Enantiomerically Pure Quinoline‐Based κ‐opiod Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation
  653. … Acid Conjugates of 2-(3,4-Dichlorophenyl)-N-methyl-N- [(1S)-1-(3-aminophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide:  κ opiod Receptor Agonists with Limited …
  654. Synthesis and opiod Receptor affinity of morphinan and benzomorphan derivatives: mixed κ agonists and μ agonists/antagonists as potential pharmacotherapeutics …
  655. Inhibitory effect of spiradoline, a κ opiod Receptor agonist, on Ca2+ induced contraction and the intracellular Ca2+ concentration in porcine coronary artery
  656. Quantitative analysis of R-84760, a selective κ–opiod Receptor agonist, in plasma by liquid chromatography with electrospray ionization tandem mass spectrometry
  657. Differential effects of specific δ and κ opiod Receptor antagonists on the bidirectional dose-dependent effect of systemic naloxone in arthritic rats, an experimental …
  658. κ opiod Receptor-mediated depression of activity evoked in convergent dorsal horn cells by thermal and non-thermal noxious stimulation
  659. … Disorder With Reduced In Vivo Norepinephrine Transporter Availability in the Locus Coeruleus” and “Association of In Vivo κ–opiod Receptor Availability and the …
  660. Involvement of κ–opiod Receptor mechanisms in the calcitonin-induced potentiation of opiod effects at the hypothalamus-pituitary-adrenocortical axis
  661. The NOP Receptor involvement in both withdrawal-and CCk-8-induced contracture responses of guinea pig isolated ileum after acute activation of κ–opiod Receptor
  662. … , ∂-, and κ–opiod Receptors and Comparisons to the Neuropeptide [Tyr1]-Leu-enkephalin: Conformations, Noncovalent Amino Acid Binding Sites, Binding Energies, Electronic Factors, and Receptor …
  663. μ-, δ-, κ-and ϵ-opiod Receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opiod peptides
  664. κ‐ and δ‐opiod Receptor functional activities are increased in the caudate putamen of cannabinoid CB1 Receptor knockout mice
  665. Solubilization and characterization of the κ–opiod Receptor type from guinea-pig cerebellum
  666. … Aerobic Oxidation of nor-Binaltorphimine (nor-BNI) Analogs without 4, 5-Epoxy Bridge Affords a More Selective Ligand for κ opiod Receptor than the Representative …
  667. A novel series of potent and selective agonists at the opiod κ–Receptor
  668. Modification of the binding of [3H] MK-801 to brain regions and spinal cord of rats treated chronically with U-50,488 H, a κ–opiod Receptor agonist
  669. Influence of temperature on the effects of μ-, δ-and κ–opiod Receptor agonists in the guinea-pig ileum myenteric plexus
  670. κ–opiod Receptor recognition sites are not modulated by local anaesthetics
  671. Comparative Analysis of Infarct Size Limiting Activity of κ–opiod Receptor Agonists in In Vivo Reperfused Heart
  672. Comparison of the in vitro efficacy of μ, δ, κ and ORL1 Receptor agonists and non-selective opiod agonists in dog brain membranes
  673. Induction of bladder sphincter dyssynergia by κ-2 opiod Receptor agonists in the female rat
  674. Species variation in effects of intrathecal κ–opiod Receptor agonist on morphine-induced itch and antinociception
  675. Lack of effect of κ–opiod Receptor agonism on long-term methamphetamine-induced neurotoxicity in rats
  676. Inhibitory effects of κ–opiod Receptor stimulation on ne-induced cardiac hypertrophy of the cultured myocardial cells
  677. [Biocytin13] Dynorphin A 1-13 Amide: A Potential Probe for the κ–opiod Receptor
  678. Antagonism of phosphoramidon-induced antinociception in mice by μ-but not κ–opiod Receptor blockers
  679. An examination of the cardiac actions of PD117, 302, a κ–opiod Receptor agonist
  680. The role of κ–opiod Receptor-induced autophagy in synaptic alterations
  681. κ and δ-opiod Receptor agonists differentially inhibit striatal dopamine and acetylcholine release
  682. Peptidomimetics of the κ–opiod Receptor. A hybrid MPCB/peptide ligand (MPCB-RRI) binds κ cloned Receptor with nanomolar affinity
  683. dextro-and levo-morphine attenuate opiod δ and κ Receptor agonist produced analgesia in μ-opiod Receptor knockout mice
  684. Mixed κ agonists and μ agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opiod Receptor binding affinity of N-substituted …
  685. Design and synthesis of 10-oxo derivative of N-cyclopropylmethyl (−)-6β-acetylthiodihydro-normorphine, a potentially κ-selective opiod Receptor ligand
  686. Serotonergic mechanisms involved in calcitonin potentiation of κ–opiod Receptor-mediated effects on adrenal secretion
  687. Role of κ–opiod Receptor agonist U-50,488 H in consummatory successive negative contrast
  688. Paradoxical locomotor activating effects of κ–opiod Receptor stimulation in the preweanling rat:: Role of the ventromedial thalamus and superior colliculus
  689. The Region in the μ opiod Receptor Conferring Selectivity for Sufentanil over the δ Receptor is Different from that over the κ Receptor
  690. KATP channels mediate the antihypertrophic effects afforded by κ–opiod Receptor stimulation in neonatal rat ventricular myocytes
  691. Structural analysis of κ‐opiod Receptor agonists
  692. Synthesis of [3H]DIPPA: A potent irreversible antagonist selective for the κ opiod Receptor
  693. Antiarrhythmic effect of κ–opiod on Cx43 in rat heart during mycardial ischemia and reperfusion via inhibiting β-adrenergic Receptor pathway
  694. Computational insights into different inhibition modes of the κ–opiod Receptor with antagonists LY2456302 and JDTic
  695. … and peripheral modification of 1-(pyrrolidin-1-ylmethyl)-2-[(6-chloro-3-oxo-indan)-formyl]-1, 2, 3, 4-tetrahydroisoquinolines as novel selective κ opiod Receptor …
  696. Effects of naloxone, morphine and κ–opiod Receptor agonists on hypoxia/hypoglycemia-induced reduction of 2-deoxyglucose uptake in hippocampal slices from U …
  697. … effect of [(±)-(2, 4, 6-cis)-4-chloro-6-(naphthalen-1-yl)-tetrahydro-2H-pyran-2-yl] methanol: participation of the NO/cGMP/KATP pathway and κ–opiod Receptor
  698. Modulation of κ–opiod Receptor mediated tolerance in the guinea-pig ileum by chronic co-administration of dihydropyridines
  699. The antinociceptive activity of κ-but not δ-opiod Receptor agonists is maintained in morphine-tolerant neuropathic rats
  700. Interaction of the adenosine A1 Receptor agonist N6-cyclopentyladenosine and κ–opiod Receptors in rat spinal cord nociceptive reflexes
  701. Amphetamine-induced preprodynorphin mRNA expression and κ–opiod Receptor binding in basal ganglia of adult rats after prenatal exposure to diazepam
  702. Selective depression of dorsal root-evoked high threshold synaptic excitation by the selective κ opiod Receptor agonist enadoline in the neonatal rat hemisected …
  703. Spinal synthesis of estrogen and concomitant signaling by membrane estrogen Receptors regulate spinal κ-and μ-opiod Receptor heterodimerization and female …
  704. The opiod Receptor subtypes μ and κ, but not δ, are involved in the control of the vasopressin and oxytocin release in the rat
  705. Comparison of the Effects of a Series of κ–opiod Receptor Agonists Upon Sodium Channel Function in Rat Brain Miniprisms
  706. opiod antagonists and drinking: evidence of κ–Receptor involvement
  707. Developmental expression of the μ, κ, and δ opiod Receptor mRNAs in mouse
  708. δ antagonist and κ agonist activity of naltriben: Evidence for differential κ interaction with the δ1 and δ2 opiod Receptor subtypes
  709. κ–opiod Receptor is involved in electroacupuncture analgesia via inhibition of spinal microglial Toll-like Receptor 4 in neuropathic pain rats
  710. Angiotensin II induced myocardial hypertrophy in neonatal rats could be attenuated by activated κ–opiod Receptor via modulating the calcineurin signal pathways
  711. Enhancement of a κ–opiod Receptor agonist-induced analgesia by L-tyrosine and L-tryptophan
  712. Effects of the κ‑opiod Receptor on the inhibition of 100 Hz electroacupuncture on cocaine‑induced conditioned place preference
  713. Stereoselective Synthesis and Pharmacological Evaluation of 2, 4-Bridged Piperidine Derivatives Designed to Activate the κ–opiod Receptor
  714. Conversion of δ-, κ-and μ-Receptor Selective opiod Peptide Agonists into δ-, κ-and μ-Selective Antagonists
  715. Discovery of an opiod κ Receptor selective pure antagonist from a library of N-substituted 4β-methyl-5-(3-hydroxyphenyl) morphans
  716. Identification of the First trans-(3R,4R)- Dimethyl-4-(3-hydroxyphenyl)piperidine Derivative To Possess Highly Potent and Selective opiod κ Receptor Antagonist …
  717. opiod μ-and κ–Receptor mediate phospholipase C activation through Gi1 in Xenopus oocytes
  718. Synthesis and opiod Receptor binding affinities of 2-substituted and 3-aminomorphinans: Ligands for μ, κ, and δ opiod Receptors
  719. A DFT Analysis of the Relationships between Electronic Structure and Human κ, δ and μ opiod Receptor Binding Affinity in a series of Diphenethylamines
  720. The opiod Receptor like-1 Receptor agonist Ro 64-6198 (1S, 3aS-8-2, 3, 3a, 4, 5, 6-hexahydro-1H-phenalen-1-yl-1-phenyl-1, 3, 8-triaza-spiro [4.5] decan-4-one) …
  721. Synthesis and Characterisation of 𝜅 opiod Receptor (KOR) Antagonists
  722. Antipruritic Activity of a Novel κ–opiod Receptor Agonist
  723. … S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a Novel Potent and Selective opiod κ Receptor …
  724. Novel κ–opiod Receptor Antagonists Derived from Salvinorin A
  725. Remifentanil post‐conditioning attenuates cardiac ischemia–reperfusion injury via κ or δ opiod Receptor activation
  726. Cloning and pharmacological characterization of a rat κ opiod Receptor
  727. Essential structure of opiod κ Receptor agonist nalfurafine for binding to κ Receptor 1: synthesis of decahydroisoquinoline derivatives and their pharmacologies
  728. STUDY OF κ–opiod Receptor EXPRESSION IN CELL CULTURES AND IN HUMAN BRAIN
  729. κ‐opiod Receptor Activation Induces the Autophagic Machinery and Alters Dendritic Spine Density
  730. The efficacy of Dynorphin fragments at the κ, μ and δ opiod Receptor in transfected HEK cells and in an animal model of unilateral peripheral inflammation
  731. Studies of μ-, κ-, and δ-opiod Receptor density and G protein activation in the cortex and thalamus of monkeys
  732. Effect of Niravoline (RU51599), a κ–opiod Receptor Agonist, on Tumour-Origin Brain Oedema
  733. Role of activation of κ–opiod Receptor in inhibiting myocardial ischemia reperfusion injury in mice
  734. Inhibition of Human CaV2. 3 Channels via μ-, δ-and κ–opiod Receptor Activation
  735. Chemical neuroanatomical and psychopharmacological evidence that κ Receptor-mediated endogenous opiod peptide neurotransmission in the dorsal and …
  736. New thoughts in mechanism research of acupuncture for myocardial stunning from κ–opiod Receptor signaling pathway
  737. κ–opiod Receptor signals through Src and focal adhesion kinase to
  738. It takes more than one κ opiod Receptor to inhibit a POMC neuron
  739. Prospects for a Novel κ–opiod Receptor Agonist, TRK-820
  740. Do activators of the κ–opiod Receptor hold the potential for anti-arrhythmic drug development?
  741. Differential modulation of κ and μ opiod antinociception by the glycine/NMDA Receptor agonist D‐serine
  742. Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opiod agonists, and selective blockade of μ-dependent inhibition by κ Receptor …
  743. Modulation of Renal Excretory Function by the Conformationally Restricted Enantiomeric κ‐opiod Receptor Agonists:(+) U‐50,488 and (−) U‐50,488
  744. Efficacy of acting κ opiod Receptor for prevention of high altitude pulmonary edema in rats
  745. Selective interference of β-arrestin 1 with κ and δ but not μ opiod Receptor/G protein coupling
  746. Discovery and biological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opiod Receptor agonist
  747. Stilbenes as κ-selective, non-nitrogenous opiod Receptor antagonists
  748. κ–opiod Receptor activation promotes mitochondrial fusion and enhances myocardial resistance to ischemia and reperfusion injury via STAT3-OPA1 pathway
  749. In silico results of κ–opiod Receptor antagonists as ligands for the second bromodomain of the Pleckstrin Homology Domain Interacting Protein
  750. Study on mechanisms of κ–opiod Receptor agonist affects neonatal rat myocardial hypertrophy induced by isoproterenol
  751. Structure of a κ–opiod Receptor misfit:(1S, 5R, 8R, 9R)-2′-hydroxy-5, 9-dimethyl-8, 2-epoxyethano-6, 7-benzomorphan hydrochloride
  752. The κ–opiod Receptor antagonist nor-binaltorphimine (nor-BNI) facilitates the development of morphine-induced behavioral sensitization
  753. Role of the Activation of Spinal κ–opiod Receptor in the Development of Spinal Centralization Induced by Remifentanil After Incision in Rats
  754. The Effects of κ–opiod Receptor Stimulation on Electrical Coupling during Ischemia in the Perfused Isolated Rat Heart
  755. 2P078 Interactions between Dynorpin and Extra Celler Loop II of κ–opiod Receptor as studied by Solid State NMR (30. Protein function (II), Poster Session, Abstract …
  756. Protective effect of κ–opiod Receptor agonist U50, 488 H pretreatment by intrathecal injection on myocardial ischemia/reperfusion injury
  757. The Widely Available Hallucinogenic Plant Salvia divinorum and Its Main Component, Salvinorin A: A Unique κ–opiod Receptor (KOP-r) Agonist with Powerful …
  758. Chronic U50, 488H abolishes inositol 1, 4, 5-trisphosphate and intracellular Ca 2+ elevations evoked by κ–opiod Receptor in rat myocytes
  759. Chronic Stress and Extended Access to Cocaine Produce Increased Drug Intake: Involvement of κ–opiod Receptor Activation
  760. Down-regulation of Spinal κ–opiod Receptor Involved in Spinal Centralization Induced by Remifentanil After Incision in Rats
  761. Agonists Specific for κ–opiod Receptor Induces Apoptosis of HCC Cells Through Enhanced Endoplasmic Reticulum Stress
  762. κ opiod Receptor Stimulation of [35S] GTPγS Binding in Guinea Pig Brain – Interaction with multiple G-proteins is not specific for any individual Gα subunit and is …
  763. Genome Mining-Based Discovery of Blenny Fish-Derived Peptides Targeting the Mouse κ–opiod Receptor
  764. β-adrenergic response modulated by κ–opiod Receptor stimulation is attenuated in the cardiomyocytes of rats following chronic hypoxia
  765. 1P103 Interaction of ECL-II of κ–opiod Receptor with dynorphin in membrane environments as revealed by solid state NMR, QCM and MD simulation (03. Membrane …
  766. Correction: In the article “κ–opiod Receptor Agonists Modulate Visceral Nociception at a Novel, Peripheral Site of Action,” by SK Joshi, Xin Su, Frank Porreca, and GF …
  767. 3P-174 Interaction of opiod peptide dynorphin with extracellular loop 2 of κ–opiod Receptor as studied by^< 13> C NMR (Biol & Artifi memb.: Structure & Property, The …
  768. … and ethanol concentrations in the nucleus accumbens during the development of reinforcement and the involvement of the κ–opiod Receptor in the modulation …
  769. Novel 3, 4, 7-Substituted Benzofuran Derivatives Having Binding Affinity to κ–opiod Receptor
  770. DIPPA: An opiod Receptor affinity label that produces selective and long-lasting κ antagonism in mice
Related Posts

Adipocyte Dedifferentiation (the Reversal of Fat Formation)

Streptococcus Mutans (Main Bacteria Behind Tooth Decay)

Cyp2e1

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping